Zimmer Biomet Q3 2024 earnings call highlights 4% net sales growth to $1.824 billion, $1.74 adjusted EPS, optimism on ERP issues, and over 50 product launches planned.
investing.com
•
30/10/2024 - 18:42 PM
Zimmer Biomet's Q3 results matched expectations, revenue rose 4%, and guidance was updated, despite ERP challenges. The company plans new product launches, including its Z1 Hip System.
investing.com
•
30/10/2024 - 10:44 AM
U.S. stocks closed mixed; Dow and S&P 500 fell, while NASDAQ rose. Significant gains for Amazon and Tesla, with Draganfly surging significantly. Market breadth favored declines.
investing.com
•
05/09/2024 - 20:30 PM
Zimmer Biomet shares fell over 8% due to ERP transition challenges, leading to potential revenue losses and slow shipments, impacting Q3 sales and EPS projections.
investing.com
•
05/09/2024 - 14:37 PM
